| Autor: |
Wen, Zhi, Rajagopalan, Adhithi, Flietner, Evan D., Yun, Grant, Chesi, Marta, Furumo, Quinlan, Burns, Robert T., Papadas, Athanasios, Ranheim, Erik A., Pagenkopf, Adam C., Morrow, Zachary T., Finn, Remington, Zhou, Yun, Li, Shuyi, You, Xiaona, Jensen, Jeffrey, Yu, Mei, Cicala, Alexander, Menting, James, Mitsiades, Constantine S., Callander, Natalie S., Bergsagel, P. Leif, Wang, Demin, Asimakopoulos, Fotis, Zhang, Jing |
| Zdroj: |
Blood; January 2021, Vol. 137 Issue: 1 p61-74, 14p |
| Abstrakt: |
NRAS Q61mutations are prevalent in advanced/relapsed multiple myeloma (MM) and correlate with poor patient outcomes. Thus, we generated a novel MM model by conditionally activating expression of endogenous NrasQ61Rand an MYCtransgene in germinal center (GC) B cells (VQ mice). VQ mice developed a highly malignant MM characterized by a high proliferation index, hyperactivation of extracellular signal-regulated kinase and AKT signaling, impaired hematopoiesis, widespread extramedullary disease, bone lesions, kidney abnormalities, preserved programmed cell death protein 1 and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain immune-checkpoint pathways, and expression of human high-risk MM gene signatures. VQ MM mice recapitulate most of the biological and clinical features of human advanced/high-risk MM. These MM phenotypes are serially transplantable in syngeneic recipients. Two MM cell lines were also derived to facilitate future genetic manipulations. Combination therapies based on MEK inhibition significantly prolonged the survival of VQ mice with advanced-stage MM. Our study provides a strong rationale to develop MEK inhibition–based therapies for treating advanced/relapsed MM. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
